Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. ABBV
3. META
4. SPY
5. IBM
6. MU
7. FDX
8. BLZE
9. NKE
10. PRIM

Go back to Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments

Sarepta Therapeutics (SRPT) Tops Q4 EPS by 29c, Revenues Beat

February 26, 2020 4:13 PM EST

Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($1.57), $0.29 better than the analyst estimate of ($1.86). Revenue for the quarter came in at $100.11 million versus the consensus estimate of $98.85 million.

The Sarepta team made great progress in service of our vision to be one of the worlds most meaningful leaders in precision genetic medicine in 2019, and profoundly so in... More